An Open Label, Parallel Two Group Clinical Study to Evaluate the Efficacy and Safety of Stretch Mark Oil and Stretch Mark Cream in Prevention and Reduction of Stretch Marks in Pregnant Women and Post- Partum Women

The Himalaya Drug Company0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•Aged >= 18 years at recruitment.
•Primigravid women.
•Singleton pregnancy.
•Women with one of the following:
•Pregnant women between 12â??14 weeks of gestation with absence of abdominal striae (for Group I).
•Post-Partum women with normal and C-section delivery and visible stretch marks (will be enrolled at the time of discharge- Post-partum - Group-II)
•Willing to participate and continue with the study follow-ups.

•Multigravida women (due to risk of having striae from an earlier pregnancy) or with already existing striae from earlier weight loss or any other reasons.
•Women taking corticosteroids for any reason (due to their association with skin striae).
•High risk pregnancy.
•Bad obstetric history.
•Any risk/ infection known to develop congenital anomaly in the baby (TORCH infections).
•Multiple pregnancies (due to increased maternal weight gain and skin stretching).
•Women with a known hypersensitivity to agents in formulation (due to risk of allergic reaction).
•Women with known disorders or illnesses that maybe associated with striae, e.g. Marfan syndrome, Cushing syndrome.
•Women who decline to discontinue other creams or lotions.
•Women who are unable to give informed consent.

发起方